(Q44412619)

2 December 2017

0 references

Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? (English)

1 reference

2 December 2017

1 reference

1

M Lynn Crismon

1 reference

2 December 2017

Anthony DeLeon

2

1 reference

2 December 2017

Alexander L Miller

series ordinal

3

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Annals of Pharmacotherapy

2 December 2017

published in

1 reference

2 December 2017

volume

37

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

738-740

1 reference

Pharmacotherapy of mental illness--a historical analysis

2 December 2017

cites work

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

21 January 2018

1 reference

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1D014

1 reference

2 December 2017

1 reference